GSK923295
GSK-923295 is a synthetic small-molecule inhibitor of kinesin-5 (KIF11), a motor protein essential for the formation and maintenance of the bipolar mitotic spindle. It was developed by GlaxoSmithKline for use in research on cell division, spindle mechanics, and cancer biology, and is cited in the literature as a tool compound for studying mitotic processes.
GSK-923295 acts by binding to the motor domain of kinesin-5 (Eg5) and inhibiting its ATPase activity. This
In preclinical research, GSK-923295 has demonstrated potent activity in cancer cell models, with inhibitory effects observed
Clinical development details for GSK-923295 are limited in publicly available sources. The compound is primarily referenced